Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Kratz

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Expert Opinion on Investigational Drugs|May 16, 2007
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trialsFelix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 19, 2014
A clinical update of using albumin as a drug vehicle - a commentaryFelix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 28, 2008
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticlesFelix Kratz
Topics in Current Chemistry|April 23, 2013
Acid-sensitive prodrugs of DoxorubicinFelix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 22, 2014
WITHDRAWN: A clinical update of using albumin as a drug vehicle - A commentaryFelix Kratz
Angewandte Chemie (International Ed. in English)|January 31, 2006
Polymer therapeutics: concepts and applicationsRainer Haag, Felix Kratz
The Journal of Organic Chemistry|January 22, 2008
2,4-Bis(hydroxymethyl)aniline as a building block for oligomers with self-eliminating and multiple release propertiesAndré Warnecke, Felix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 19, 2012
Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systemsFelix Kratz, André Warnecke
Bioconjugate Chemistry|March 20, 2003
Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacyAndré Warnecke, Felix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 14, 2011
Clinical impact of serum proteins on drug deliveryFelix Kratz, Bakheet Elsadek
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|May 16, 2007
DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trialsFelix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 19, 2014
A clinical update of using albumin as a drug vehicle - a commentaryFelix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 28, 2008
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticlesFelix Kratz
Topics in Current Chemistry|April 23, 2013
Acid-sensitive prodrugs of DoxorubicinFelix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 22, 2014
WITHDRAWN: A clinical update of using albumin as a drug vehicle - A commentaryFelix Kratz
Angewandte Chemie (International Ed. in English)|January 31, 2006
Polymer therapeutics: concepts and applicationsRainer Haag, Felix Kratz
The Journal of Organic Chemistry|January 22, 2008
2,4-Bis(hydroxymethyl)aniline as a building block for oligomers with self-eliminating and multiple release propertiesAndré Warnecke, Felix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 19, 2012
Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systemsFelix Kratz, André Warnecke
Bioconjugate Chemistry|March 20, 2003
Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacyAndré Warnecke, Felix Kratz
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 14, 2011
Clinical impact of serum proteins on drug deliveryFelix Kratz, Bakheet Elsadek
Pageof 8